Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This
occurs as a result of destructive changes in an area of the brain responsible for making
dopamine, the basal ganglia. Patients with the disease experience, rigid muscles, stooped
posture, and a shuffling-type walk (gait).
In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the
treatment of Parkinson's Disease. Eliprodil works by blocking special receptors (NMDA) that
are associated with the symptoms of Parkinson's Disease.
The objectives of this study are to evaluate the acute effects of the NR2B subtype-selective
NMDA antagonist eliprodil on levodopa-associated motor response complications in patients
with advanced Parkinson's Disease (PD).
All patients will carry a diagnosis of idiopathic Parkinson's Disease based on the
presence of a characteristic clinical history and neurologic findings. Most will have
relatively advanced disease with associated motor response complications.
Males and females between the ages of 18-75.
No presence or history of any medical condition that can reasonably be expected to subject
the patient to unwarranted risk.
No patients with baseline QTc prolongation (greater than 440 msec).
No pregnant women nor those not practicing effective means of birth control.